Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
Repare Therapeutics (Nasdaq: RPTX) will present new data from Module 1 of its ongoing Phase 1/2 TRESR clinical trial at the ESMO Congress 2024 in Barcelona. The trial evaluates camonsertib monotherapy in patients with advanced solid tumors harboring ATM loss-of-function. TRESR (NCT04497116) is a first-in-human, multi-center, open-label study designed to establish the recommended Phase 2 dose and schedule, while assessing safety, pharmacokinetics, and preliminary anti-tumor activity. Dr. Benedito A. Carneiro from Brown University will deliver an oral presentation on September 14, sharing insights on camonsertib's performance in treating these specific cancer types.
Repare Therapeutics (Nasdaq: RPTX) presenterà nuovi dati dal Modulo 1 del suo studio clinico in fase 1/2 TRESR al Congresso ESMO 2024 a Barcellona. Lo studio valuta la monoterapia con camonsertib in pazienti con tumori solidi avanzati che presentano una perdita di funzione dell'ATM. TRESR (NCT04497116) è uno studio di fase iniziale, multicentrico e aperto, progettato per stabilire la dose e il programma raccomandati per la fase 2, valutando nel contempo sicurezza, farmacocinetica e attività antitumorale preliminare. Il Dott. Benedito A. Carneiro dell'Università di Brown presenterà un intervento orale il 14 settembre, condividendo approfondimenti sulle prestazioni del camonsertib nel trattamento di questi specifici tipi di cancro.
Repare Therapeutics (Nasdaq: RPTX) presentará nuevos datos del Módulo 1 de su ensayo clínico en fase 1/2 TRESR en el Congreso ESMO 2024 en Barcelona. El ensayo evalúa la monoterapia con camonsertib en pacientes con tumores sólidos avanzados que presentan pérdida de función del ATM. TRESR (NCT04497116) es un estudio en primera fase, multicéntrico y abierto, diseñado para establecer la dosis y el programa recomendados para la fase 2, mientras se evalúan la seguridad, la farmacocinética y la actividad antitumoral preliminar. El Dr. Benedito A. Carneiro de la Universidad de Brown dará una presentación oral el 14 de septiembre, compartiendo información sobre el rendimiento del camonsertib en el tratamiento de estos tipos específicos de cáncer.
Repare Therapeutics (Nasdaq: RPTX)는 바르셀로나에서 열리는 ESMO Congress 2024에서 진행 중인 1/2상 TRESR 임상 시험의 모듈 1에 대한 새로운 데이터를 발표할 예정이다. 이 시험은 선진 고형 종양에서의 카모세르티브 단독 치료를 평가하며, ATM 기능 상실을 가진 환자를 대상으로 한다. TRESR (NCT04497116)은 사람을 대상으로 하여 다기관으로 진행되는 공개 연구로, 2상에서의 권장 용량과 일정을 설정하는 동시에 안전성, 약동학, 초기 항종양 활성을 평가하기 위해 설계되었다. 브라운 대학교의 벤에디토 A. 카르네이로 박사가 9월 14일에 구두 발표를 진행하여, 이러한 특정 암 유형을 치료하는 카모세르티브의 성과에 대한 통찰력을 공유할 예정이다.
Repare Therapeutics (Nasdaq: RPTX) présentera de nouvelles données du Module 1 de son essai clinique de phase 1/2 TRESR au Congrès ESMO 2024 à Barcelone. L'essai évalue la monothérapie par camonsertib chez des patients atteints de tumeurs solides avancées présentant une perte de fonction de l'ATM. TRESR (NCT04497116) est une étude de première expérience humaine, multicentrique et ouverte, conçue pour établir la posologie et le calendrier recommandés pour la phase 2, tout en évaluant la sécurité, la pharmacocinétique et l'activité antitumorale préliminaire. Le Dr Benedito A. Carneiro de l'Université de Brown présentera une communication orale le 14 septembre, partageant des informations sur les performances du camonsertib dans le traitement de ces types de cancer spécifiques.
Repare Therapeutics (Nasdaq: RPTX) wird auf dem ESMO Kongress 2024 in Barcelona neue Daten aus Modul 1 seiner laufenden Phase 1/2 TRESR klinischen Studie präsentieren. Die Studie bewertet die Monotherapie mit Camonsertib bei Patienten mit fortgeschrittenen soliden Tumoren mit ATM Funktionsverlust. TRESR (NCT04497116) ist eine Erst-in-Menschen, multizentrische, offene Studie, die darauf abzielt, die empfohlene Dosis und den Zeitplan für Phase 2 festzulegen, während sie Sicherheit, Pharmakokinetik und erste Hinweise auf antitumorale Aktivität untersucht. Dr. Benedito A. Carneiro von der Brown University wird am 14. September einen mündlichen Vortrag halten und Einsichten zur Leistung von Camonsertib bei der Behandlung dieser spezifischen Krebsarten teilen.
- Repare Therapeutics is presenting new data from its Phase 1/2 TRESR clinical trial at ESMO Congress 2024
- The trial focuses on camonsertib monotherapy for advanced solid tumors with ATM loss-of-function
- The study aims to establish the recommended Phase 2 dose and schedule for camonsertib
- None.
TRESR (NCT04497116) is a first-in-human, multi-center, open-label Phase 1/2 dose-escalation and expansion study designed to establish the recommended Phase 2 dose (RP2D) and schedule. The study evaluated safety, pharmacokinetics and identify preliminary anti-tumor activity associated with camonsertib monotherapy in patients with solid tumors (Module 1).
Oral Presentation Details:
Title: Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)
Presenter: Benedito A. Carneiro, MD, Legorreta Cancer Center, Division of Hematology/Oncology, The Warren Alpert Medical School, Brown University,
Presentation number: 619MO
Session: Mini Oral Session: Developmental Therapeutics
Session date and time: Saturday, September 14 | 8:45 a.m. – 10:15 a.m. ET
Session location: Oviedo Auditorium, Hall 3
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240913906467/en/
Investor Relations & Media:
Robin Garner
Vice President and Head of Investor Relations
Repare Therapeutics Inc.
investor@reparerx.com
Source: Repare Therapeutics Inc.
FAQ
What is the purpose of Repare Therapeutics' TRESR clinical trial for camonsertib (RPTX)?
When and where will Repare Therapeutics (RPTX) present the TRESR trial data for camonsertib?
Who will be presenting the TRESR trial results for Repare Therapeutics' camonsertib (RPTX) at ESMO 2024?
What type of cancer patients are included in Repare Therapeutics' TRESR trial for camonsertib (RPTX)?
